For Research Use Only - Not for Human Consumption
A peptide COA discrepancy example is not automatically evidence of a failed batch. It is a signal to stop, compare source records, and determine whether the mismatch reflects a transcription error, a reporting convention, a method difference, or a true analytical concern. For a research buyer, the distinction matters: a certificate of analysis is only useful when its reported result can be tied to the exact material, method, and batch received.
For Research Use Only - Not for Human Consumption. Research-grade materials must be handled only by qualified personnel in appropriate laboratory settings. They are not intended for diagnostic, therapeutic, veterinary, food, cosmetic, or personal use.
> Compliance Notice
> For Research Use Only - Not for Human Consumption. This article addresses analytical documentation and batch verification for laboratory materials. It does not provide instructions for human or animal administration.
What a COA Must Establish
A usable peptide COA is more than a purity percentage printed beside a lot number. At minimum, it should establish a documented chain between the vial label, the manufacturing batch, the analytical sample, and the final reported result. A reviewer should be able to identify the material name, batch or lot identifier, test date, analytical method, acceptance criterion, result, and authorized release information.
For lyophilized synthetic peptides, identity and purity are separate questions. Identity is commonly assessed with LC-MS or another mass-spectrometric technique. Purity is frequently reported from reversed-phase HPLC or UPLC chromatographic area integration. Peptide content, residual solvents, water content, counterion content, and microbial controls may also be relevant, depending on the material specification and research workflow.
A stated result such as “99.2% HPLC purity” does not mean every other property has been measured at 99.2%, nor does it establish absolute peptide mass fraction. It means that, under the stated chromatographic method and integration approach, the principal peak represented 99.2% of the integrated detector response. That distinction is central when reviewing a discrepancy.
A Peptide COA Discrepancy Example
Consider a hypothetical 10 mg lyophilized peptide vial labeled Batch PS-240718. The supplier-provided COA lists a molecular mass result consistent with the target analyte and reports 99.3% purity by RP-HPLC. A later third-party report references the same batch number but lists 98.7% purity. The molecular-mass result remains consistent across both documents.
At first glance, a 0.6 percentage-point difference can look disqualifying. It may not be. The first question is whether both laboratories used comparable methods. One report may use a C18 column with a 0.1% trifluoroacetic acid mobile-phase modifier and UV detection at 214 nm. The other may use formic acid, a different gradient, a different column geometry, and integration settings that resolve a small adjacent peak differently. Both results can be analytically defensible while not being numerically interchangeable.
The review should then move from the percentage to the underlying chromatograms. Does each report show the same principal retention region? Are minor peaks labeled and integrated? Is the reported percentage an area-percent value, a normalized value, or a calculation corrected against a reference standard? If one lab excludes a solvent-front artifact and another includes it, the reported purity can diverge without suggesting a different material.
The batch match also deserves close inspection. “Batch PS-240718” must match exactly across the vial label, COA, analytical worksheet, sample-receipt record, and invoice. Similar lot numbers, relabeled inventory, or a report issued for a retained manufacturing sample rather than the finished packaged unit can create apparent agreement that is weaker than it looks.
A second hypothetical case is more serious. The manufacturer COA reports 99.1% purity for Batch PS-240718, while the independent laboratory report identifies a principal mass that does not align with the expected molecular mass or shows a substantially different chromatographic profile. Here, matching batch text alone is insufficient. The material should be placed on documentation hold while chain-of-custody records, sample handling, instrument calibration status, raw data, and a retained sample are reviewed.
Separate Method Differences From Material Differences
The most efficient investigation starts with a side-by-side data table, not a general request for reassurance. Compare the test article name, batch number, sample weight, report date, laboratory identity, test method, system-suitability criteria, detector wavelength, chromatographic conditions, calculated result, and release specification.
Method variability is expected within limits. HPLC purity can vary when laboratories use different stationary phases, gradient programs, mobile-phase additives, temperatures, detectors, integration thresholds, or peak-processing rules. Some peptides also present closely eluting species that are sensitive to method selectivity. A small numerical difference may therefore be explainable.
However, several findings warrant escalation: a nonmatching molecular mass, a missing batch identifier, a report with no method designation, chromatograms that do not support the stated result, unexplained additional major peaks, or a COA that reports only a generic purity claim without a date or authorized signoff. The practical threshold depends on the buyer’s pre-established specification. A laboratory requiring a minimum of 99% area purity may treat 98.7% differently from a laboratory conducting preliminary analytical work, but neither should substitute assumptions for documentation.
Questions to Send to the Supplier or Testing Laboratory
A precise request produces a useful answer. Ask whether the COA was generated from the finished lot, a manufacturing retain, or an in-process sample. Request confirmation that the tested sample and shipped vial share the same batch identifier. Ask for the chromatogram, the method summary, and the integration parameters used to calculate purity.
For identity, request the observed mass, expected mass, ionization mode, charge state assignment, and mass tolerance. For purity, ask whether the result is area percent by HPLC, assay by an orthogonal quantitative method, or a mass-balance estimate. These are not interchangeable data types.
If the supplier provides a manufacturer COA and independent verification, identify which report controls release and whether the independent sample was drawn from the same finished batch. A third-party report adds value when its provenance is clear. It does not replace traceability merely because it bears an outside laboratory name.
Relevant laboratory expectations are described in established analytical frameworks, including USP <621> Chromatography, USP <1225> Validation of Compendial Procedures, and ICH Q2(R2) Validation of Analytical Procedures. These references do not prescribe one universal peptide method. They provide a disciplined basis for judging specificity, precision, accuracy, reportable range, and documentation.
How to Document the Resolution
Close a discrepancy only after the explanation is recorded against the batch. The resolution should state what differed, why it differed, which evidence was reviewed, whether the materials were confirmed to be the same, and whether the result meets the buyer’s acceptance criteria. Retain the original COAs rather than replacing one PDF with another.
For example: “Batch PS-240718 manufacturer result, 99.3% by RP-HPLC, and third-party result, 98.7% by RP-UPLC, were reviewed. Batch identifiers matched across shipment and sample-receipt records. LC-MS identity was consistent with the specified analyte in both reports. Method differences included column chemistry and integration treatment of a minor adjacent peak. Material accepted against the laboratory’s minimum 98.5% HPLC area-purity criterion.” That entry is concise, auditable, and more useful than an email stating that the discrepancy was “resolved.”
At Peptide Source, a quality-focused review should begin with batch-specific documentation, stated purity criteria, and independent verification where available. A 99% purity standard is meaningful only when the testing method, batch traceability, and released records support it.
For Research Use Only - Not for Human Consumption
COAs support purchasing and laboratory quality decisions. They do not establish suitability for any use outside controlled research. For Research Use Only - Not for Human Consumption.
The right response to a COA mismatch is neither automatic rejection nor automatic acceptance. Compare the methods, confirm the batch, inspect the analytical evidence, and document the decision before the material enters a research workflow.